FluroTech LTD. (TSXV: $TEST) (OTCQB: $FLURF) announces that FluroTech has acquired all of the shares of FluroTest not currently owned by FluroTech.
Read news: https://t.co/l7rkfJ2Knh
FluroTest has made a lot of progress on our journey towards preparing for commercial deployment with our partners.
✔️ Proof of concept has been successfully achieved
✔️ Patent applications have been filed
Subscribe to stay up to date: https://t.co/Yc2NGtstm4
FluroTech LTD. (TSXV: $TEST) (OTCQB: $FLURF) announced it has filed its Pre-EUA Request with the FDA. The Pre-EUA submission is the latest step taken as it seeks authorization of its FluroTest Pandemic Response Platform.
Read News Release ➡️ https://t.co/OBATfuUfQF
Business continuity has been shattered. In the U.S alone an estimated $3.2 trillion GDP will be lost in a 2-year period. As of April 2021, an estimated 1 in 4 Americans - almost 90 million people - say they will refuse #Covid19 vaccination.
The US FDA has acknowledged the vital role of high-throughput #antigen tests in the overall response to #COVID19 and in September 2020, FluroTest LLC confirmed the successful function of its point-of-care, rapid antigen test.
Learn more: https://t.co/oiIyYtFoYZ
FluroTest (#TSXV: $TEST | #OTCQB: $FLURF) is developing a new diagnostic solution that will drive economic recovery with a rapid antigen testing platform.
For all investor inquiries, please contact our Investor Relations representative, MarketSmart → https://t.co/XKU0BNz5Jv
As the world’s nations begin to strategize about the safest plan to reopen large drivers of our economy, accurate and real-time health information for all individuals is paramount.
Learn more: https://t.co/COxiilkYLS
Built to make frequent testing fast, convenient, highly reliable and affordable, and all at the point-of-collection, $TEST rapid #antigen testing platform will be essential for accurate viral detection while helping to restore and stimulate social and economic activity.
The global #COVID19 saliva screening test potential market size was valued at USD 2955.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.8% from 2021 to 2028. (Source: Grandview Research)
"FluroTest has the resources in place to pursue test verification and validation, and remain on track with our @US_FDA submission preparation,” said Bill Phelan, CEO. “We believe $TEST is positioned to address this need, and will be successful as it is purpose-built...”
FluroTest is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly efficient testing for significant numbers of people.
Never miss an update. Subscribe: https://t.co/Yc2NGtstm4
FluroTech LTD. (TSXV: $TEST) (OTCQB: $FLURF) is pleased to be recognized in Grand View Research’s June 2021 report: COVID-19 Saliva Screening Test Potential Market. https://t.co/eS3a3Xfdf4
FluroTest is pleased to share initial concept models for the pre-production Pandemic Defense Systems being developed by Hudson Robotics.
Learn more about FluroTest's relationship with laboratory robotics automation partner, Hudson Robotics: https://t.co/sjFNJmiCJ1
$TEST $FLURF
#Antigen testing is a critical tool to help end the crisis by identifying those who are actively contagious and infected with SARS-CoV-2, the virus that causes COVID-19.
Learn more: https://t.co/COxiilkYLS
Even #vaccinated people need to supple a negative Covid test to get onto a cruise...
"All guests were required to show a negative #Covid19 test and proof of #vaccination 72 hours before its departure on Saturday, the company said." #newnormal
https://t.co/KUEj3RGxml
The key to getting people back to a full, healthy life is the ability to scale access to accurate, #rapid, and affordable #testing. High efficiency. 2,500 tests an hour. Individual results in 5 minutes.
Learn more about $TEST → https://t.co/2JggBapmSw
Measuring and quantifying the antigens present in an individual could help determine just how contagious the disease is. That's important as it appears to be able to spread before an individual exhibits symptoms.